Lori Lyons-Williams

Next week at the 4th #TRPSummit2025, Abdera CTO Kawa Chiu takes the stage to chair Day 1 & weigh in on two panels, covering real-world evidence in RLT trial design & the future of talent in radiopharma. Kawa’s perspective is shaped by years at the forefront of targeted #radiotherapeutics. We're excited to see her help lead the conversation in San Diego.

The Abdera team was proud to attend #AACR25, where we presented a Trial-in-Progress for our Phase 1 study of ABD-147 and unveiled our second lead program, ABD-320. We're energized by the progress across #oncology and remain committed to advancing novel radiopharmaceutical therapies for patients.

Heading to #JPM25? Abdera President & CEO Lori Lyons-Williams will present on Mon, Jan 13 at 10:30 a.m. PR, highlighting the company’s progress & key milestones, including the recent initiation of our first-in-human Phase 1 clinical trial for ABD-147 & preclinical data for ABD-320. Learn more here: businesswire.com/news/home/2…

Employees like Gabriel are at the heart of what we are set out to accomplish at Abdera. Our team is filled with curious and creative minds who come together everyday to bring new hope to those facing devastating diagnoses. To join our team, visit abderatx.com.

We loved seeing some of the Abdera team hit the pavement running at the JP Morgan Corporate Challenge in San Francisco! Cheers to a great event, supporting the community, and moving together toward a healthier future. #JPMCC

We’re committed to building a team that’s focused on offering new hope to families facing devastating diseases. It’s passionate leaders like Kimberly that continue to drive our mission to transform how #cancer is treated. Learn more and join our team at abderatx.com.

We're excited to announce the Orphan Drug Designation granted by the @ US_FDA to ABD-147 for the treatment of neuroendocrine carcinoma. Learn more about this next-generation precision #radiopharmaceutical therapy here: abderatx.com/press-releases/…

We’re honored to be recognized as a top innovator in #biotech on @FierceBiotech #Fierce15 list. We're in the pursuit to develop better, optimized therapies for people living with #cancer and we couldn't be more proud of what our team is accomplishing! fiercebiotech.com/special-re…

We’re excited to announce today $142M in financing that enables us to design and develop tunable, antibody-based radiopharmaceuticals for #cancer. Learn more here: abderatx.com/press-releases/…